Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ICU with free AI briefings, catalyst countdowns, and dilution alerts.

ICU · SeaStar Medical Holding Corporation

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4M Cash on Hand
3.8mo Cash Runway
3.3% Short Interest
$10 Analyst Target (2)
Follow ICU by email Get an email when ICU reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ICU, unsubscribe in one click. Privacy

📣 What ICU Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

💰 Cash Runway & Dilution Risk

ICU holds $4M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.2M/quarter from operations, an estimated runway of 3.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ICU files for a raise →

👥 Who Owns ICU

Insiders 2.6% Institutions 18.6% Public and other holders 78.8%
HolderTypeShares% of sharesAs of
Mitchell P. Kopin Institution (13G, 5%+) 489,105 9.20% 2026-09-30
Ayrton Capital LLC Institution (13G, 5%+) 278,436 5.24% 2026-03-31
LPL Financial LLC Institution (13F) 66,801 1.26% 2026-09-30
Geode Capital Management, LLC Institution (13F) 51,009 0.96% 2026-09-30
Eric Schlorff
Chief Executive Officer
Insider 50,140 0.94% 2026-07-01
Vanguard Capital Management LLC Institution (13F) 33,091 0.62% 2026-09-30
Kevin Chung
Chief Medical Officer
Insider 28,021 0.53% 2026-07-01
UBS Group AG Institution (13F) 26,614 0.50% 2026-09-30
John Neuman
Director
Insider 16,200 0.30% 2026-07-01
Vanguard Fiduciary Trust Co Institution (13F) 13,692 0.26% 2026-09-30
HRT Financial LP Institution (13F) 12,579 0.24% 2026-09-30
Heel Kenneth Van
Director
Insider 11,940 0.22% 2026-07-01

Share count 5,315,967 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-18
filed 2026-08-19
Messinger Michael
Purchase (P) 750 $3.27 2,500
2026-07-01
filed 2026-07-02
Schlorff Eric
Award (A) 10,288 – 50,140
2026-07-01
filed 2026-07-02
Chung Kevin
Award (A) 7,202 – 28,021
2026-07-01
filed 2026-07-02
Vincent Bernadette N
Award (A) 4,000 – 8,200
2026-07-01
filed 2026-07-02
Neuman John
Award (A) 4,000 – 16,200

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ICU picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ICU and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.